目的观察美菲康不同给药途径治疗癌痛的临床疗效和不良反应。方法112例癌痛患者分成两组,A组56例口服给药,B组为不能正常进食的癌痛患者56例,直肠给药。初始剂量均为30mg,12h给药1次。结果A、B组疼痛明显缓解率分别为89.3%及87.5%,经统计学处理无明显差异。结论美菲康直肠给药疗效确切,值得临床应用。 Objective To observe the clinical efficacy and side effects of different routes of administration for Meifefuk in the treatment of cancer pain. Methods One hundred and twelve patients with cancer pain were divided into two groups. Group A received oral administration of 56 cases, Group B received 56 cases of cancer pain without normal consumption, and rectal administration. The initial dose was 30mg, 12h administered 1 time. Results The pain relief rates in groups A and B were 89.3% and 87.5%, respectively, and no significant difference was found after statistical analysis. Conclusions Mefikang rectal delivery is effective and worthy of clinical application.